Srini Tenjarla
Overview
Explore the profile of Srini Tenjarla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salamat-Miller N, Turner M, Bandekar A, Dixit N, Jochim E, Mangum B, et al.
World J Pediatr
. 2022 Nov;
19(1):58-67.
PMID: 36344872
Background: Recombinant human (rh)IGF-1/IGFBP-3 protein complex, administered as a continuous intravenous infusion in preterm infants, is being studied for the prevention of complications of prematurity. Methods: We conducted in vitro...
2.
Tenjarla S
Drugs R D
. 2015 Jun;
15(2):211-5.
PMID: 26115756
Introduction: Mesalamine (5-aminosalicylic acid; 5-ASA) is recommended first-line therapy for mild-to-moderate ulcerative colitis. Many mesalamine formulations employ a pH-dependent release mechanism designed to maximize drug release in the colon. This...
3.
Abinusawa A, Tenjarla S
Adv Ther
. 2015 May;
32(5):477-84.
PMID: 25951927
Introduction: Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate...
4.
Tenjarla S, Abinusawa A
Adv Ther
. 2010 Nov;
28(1):62-72.
PMID: 21088944
Introduction: Substantial variability in gastrointestinal pH is observed in patients with ulcerative colitis (UC). We characterized the effect of pH on 5-aminosalicylic acid (5-ASA) release from MMX mesalamine tablets (Shire...
5.
Tenjarla S, Romasanta V, Zeijdner E, Villa R, Moro L
Adv Ther
. 2007 Sep;
24(4):826-40.
PMID: 17901032
5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcerative colitis, a chronic inflammatory condition that most commonly affects the distal part of the colon. MMXtrade mark...